These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 28965781)
1. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. Houston KA; King J; Li J; Jemal A J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781 [TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061 [TBL] [Abstract][Full Text] [Related]
3. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017. Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230 [TBL] [Abstract][Full Text] [Related]
4. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057 [TBL] [Abstract][Full Text] [Related]
5. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality. Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008 [TBL] [Abstract][Full Text] [Related]
6. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening. Jemal A; Culp MB; Ma J; Islami F; Fedewa SA J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713 [TBL] [Abstract][Full Text] [Related]
7. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052 [TBL] [Abstract][Full Text] [Related]
8. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851 [TBL] [Abstract][Full Text] [Related]
9. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation. Lai SM; Keighley J; Garimella S; Enko M; Parker WP JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715 [TBL] [Abstract][Full Text] [Related]
10. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. Dall'Era MA; deVere-White R; Rodriguez D; Cress R Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368 [TBL] [Abstract][Full Text] [Related]
12. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. Hankey BF; Feuer EJ; Clegg LX; Hayes RB; Legler JM; Prorok PC; Ries LA; Merrill RM; Kaplan RS J Natl Cancer Inst; 1999 Jun; 91(12):1017-24. PubMed ID: 10379964 [TBL] [Abstract][Full Text] [Related]
13. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer. Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252 [TBL] [Abstract][Full Text] [Related]
14. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States. Kelly SP; Anderson WF; Rosenberg PS; Cook MB Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421 [TBL] [Abstract][Full Text] [Related]
15. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392 [TBL] [Abstract][Full Text] [Related]
16. Trends in Incidence of Metastatic Prostate Cancer in the US. Desai MM; Cacciamani GE; Gill K; Zhang J; Liu L; Abreu A; Gill IS JAMA Netw Open; 2022 Mar; 5(3):e222246. PubMed ID: 35285916 [TBL] [Abstract][Full Text] [Related]
17. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Eapen RS; Herlemann A; Washington SL; Cooperberg MR Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220 [TBL] [Abstract][Full Text] [Related]
18. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016). Schmanke K; Okut H; Ablah E Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304 [TBL] [Abstract][Full Text] [Related]
19. Trends in prostate cancer mortality among black men and white men in the United States. Chu KC; Tarone RE; Freeman HP Cancer; 2003 Mar; 97(6):1507-16. PubMed ID: 12627516 [TBL] [Abstract][Full Text] [Related]
20. The Association of County-level Prostate-specific Antigen Screening with Metastatic Prostate Cancer and Prostate Cancer Mortality. Stone BV; Labban M; Beatrici E; Filipas DK; D'Amico AV; Lipsitz SR; Choueiri TK; Kibel AS; Cole AP; Iyer HS; Trinh QD Eur Urol Oncol; 2024 Jun; 7(3):563-569. PubMed ID: 38155059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]